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IgG and IgM Autoantibody Differences in Discoid
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Benjamin F. Chong1, Lin-chiang Tseng1, Thomas Lee1, Rebecca Vasquez1, Quan Z. Li2,
Song Zhang3, David R. Karp2, Nancy J. Olsen4 and Chandra Mohan2
Systemic lupus erythematosus (SLE) patients with discoid lupus erythematosus (DLE) were reported to have
milder disease. To test this observation, we used sandwich arrays containing 98 autoantigens to compare
autoantibody profiles of SLE subjects without DLE (DLESLEþ ) (N¼ 9), SLE subjects with DLE (DLEþ SLEþ )
(N¼ 10), DLE subjects without SLE (DLEþ SLE) (N¼ 11), and healthy controls (N¼ 11). We validated
differentially expressed autoantibodies using immunoassays in DLESLEþ (N¼ 18), DLEþ SLEþ (N¼ 17),
DLEþ SLE (N¼ 23), and healthy subjects (N¼ 22). Arrays showed 15 IgG autoantibodies (10 against nuclear
antigens) and 4 IgM autoantibodies that were differentially expressed (q-valueo0.05). DLESLEþ subjects had
higher IgG autoantibodies against double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), double-
stranded RNA (dsRNA), histone H2A and H2B, and SS-A (52 kDa) compared with all other groups including
DLEþ SLEþ subjects (Po0.05). Immunoassays measuring anti-dsDNA, -ssDNA, and -SS-A (52 kDa) IgG
autoantibodies showed similar trends (Po0.05). Healthy and DLEþ SLE subjects expressed higher IgM
autoantibodies against alpha beta crystallin, lipopolysaccharide, heat-shock cognate 70, and desmoglein-3
compared with DLEþ SLEþ and DLESLEþ subjects. IgG:IgM ratios of autoantibodies against nuclear antigens
progressively rose from healthy to DLESLEþ subjects. In conclusion, lower IgG autoantibodies against nuclear
antigens in DLEþ SLEþ versus DLESLEþ subjects suggest that DLE indicates lower disease severity. Higher
IgM autoantibodies against selected antigens in healthy and DLEþ SLE subjects may be nonpathogenic.
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INTRODUCTION
Discoid lupus erythematosus (DLE), which is present in up to
20% of systemic lupus erythematosus (SLE) patients (Uramoto
et al., 1999), is associated with milder SLE disease activity and
lower prevalence of lupus nephritis (Gilliam et al., 1974;
Prystowsky and Gilliam, 1975; Merola et al., 2011). In all,
21–63% of DLE patients have antinuclear antibodies (ANAs)
(Millard and Rowell, 1979; Callen, 1982; Wallace, 1993), but
o5% have significant ANA titers (41:320) seen in SLE
patients (Costner and Sontheimer, 2008). However, less
information is available about autoantibody specificity com-
parisons between different subsets of DLE and SLE patients.
Proteomic technologies have enhanced our ability to
simultaneously and efficiently assess multiple autoantibodies
in patient sera. To provide comprehensive autoantibody
profiles of patients, Robinson et al. (2002) devised miniatur-
ized arrays that contained purified autoantigens. Addition of
patient sera and fluorescent secondary antibodies to these
arrays facilitates the simultaneous detection of numerous
autoantibodies. Moreover, these arrays demonstrate 4- to 8-
fold greater sensitivity in detecting the presence of auto-
antibodies than ELISAs.
Autoantigen arrays have generated autoantibody profiles
that can discriminate patient groups and provide insight into
disease progression. In lupus nephritis patients, autoantigen
arrays showed that anti-single-stranded DNA (ssDNA), anti-
double-stranded DNA (dsDNA), and anti-glomerular anti-
bodies correlated with clinical severity (Li et al., 2005). Our
group recently used autoantigen arrays comparing incom-
plete lupus subjects, who were defined as having one to three
American College of Rheumatology (ACR) SLE diagnostic
criteria, and SLE subjects. Incomplete lupus subjects showed
higher levels of IgM autoantibodies against nuclear antigens
and collagens than SLE subjects. This important finding might
aid in distinguishing incomplete lupus erythematosus from
SLE (Li et al., 2007).
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Comparing autoantibody profiles in DLE and SLE subjects
may uncover autoantibodies that distinguish these two
entities, and shed light on the pathogenesis of DLE. Hence,
we conducted a cross-sectional pilot study using autoantigen
arrays to compare autoantibody profiles of age- and gender-
matched subjects in four groups: (1) SLE subjects without DLE
(DLESLEþ ), (2) DLE subjects with SLE (DLEþ SLEþ ), (3)
DLE subjects without SLE (DLEþ SLE), and (4) healthy
controls. We also performed ELISAs and fluorescent immuno-
assays to validate differentially expressed autoantibodies in
the sera of these subjects. We hypothesized that the levels
and types of autoantibodies against nuclear and non-nuclear
antigens would discriminate these four groups.
RESULTS
Subject characteristics
The characteristics of age- and gender-matched DLESLEþ
(N¼ 9), DLEþ SLEþ (N¼ 10), DLEþ SLE (N¼11), and
healthy control (N¼11) subjects that were recruited and
seroprofiled using autoantigen arrays are displayed in Table 1.
The characteristics of the expanded cohort of age- and
gender-matched DLESLEþ (N¼18), DLEþ SLEþ (N¼17),
DLESLEþ (N¼23), and healthy control (N¼22) subjects
recruited to confirm array findings via ELISAs and fluorescent
immunoassays are displayed in Table 2. All subjects whose
sera were evaluated by autoantigen arrays were included in
this cohort.
Autoantigen arrays show distinctive patterns of IgG
autoantibodies against nuclear antigens in DLE and SLE subjects
The serum levels of 65 IgG autoantibodies meeting minimal
net fluorescence intensity (NFI) requirements are presented in
a heat map clustered by autoantigen and subject group in
Figure 1a. Significance analysis of microarrays (SAMs)
analysis generated a total of 15 IgG autoantibodies that were
differentially expressed among the four groups (qo0.05)
(asterisked in Figure 1a). These included IgG antibodies to
C1q, centromere protein-A, desmoglein-3, dsDNA, double-
stranded RNA (dsRNA), fibrinogen I-S, histone H1, histone
H2A, histone H2B, platelet-derived growth factor receptor
beta, rat glomeruli, SS-A (52 kDa), SS-A (60 kDa), ssDNA, and
U1-snRNP-BB0. Ten of these autoantibodies targeted nuclear
antigens (anti-centromere protein-A, -dsDNA, -dsRNA, -
histone H1, -histone H2A, -histone H2B, -SS-A (52 kDa), -
SS-A (60 kDa), -ssDNA, and U1-snRNP-BB0) (bracketed in
Figure 1a). Autoantibodies targeting dsDNA and SS-A
(52 kDa) had the highest levels, with levels of the other
autoantibodies being one or two logarithms lower. Both SLE
groups showed similar ranges of autoantibody levels.
DLESLEþ subjects expressed the highest levels of auto-
antibodies against the aforementioned nuclear antigens
(Po0.05) except for anti-centromere protein-A (Figure
1b–k). Most of these autoantibodies showed a stepwise
downward progression, starting with DLESLEþ subjects
and followed by DLEþ SLEþ , DLEþ SLE, and healthy
subjects. It is noteworthy that anti-dsDNA, -dsRNA, -histone
H2A, -histone H2B, -SS-A (52 kDa), and -ssDNA antibodies
were significantly higher in DLESLEþ subjects compared
Table 1. Patient characteristics (cohort used for
autoantigen arrays)
Normal DLE+SLE DLE+SLE+ DLESLE+ P-value*
N 11 11 10 9 —
Gender (F) 10 11 9 8 0.78
Age at visit, mean (SD) 45 (11) 46 (12) 48 (12) 44 (11) 0.88
Ethnicity, N (%)
Caucasian 5 (45) 4 (36) 4 (40) 1 (11) 0.42
African American 5 (45) 7 (64) 4 (40) 5 (56) 0.76
Hispanic 1 (10) 0 (0) 2 (20) 3 (33) 0.15
CLASI activity score, mean
(SD)**
NA 9 (9) 10 (7) NA 0.86
CLASI damage score, mean
(SD)**
NA 7 (5) 10 (9) NA 0.35
SLEDAI score, mean (SD)*** NA 3 (3) 4 (2) 2 (4)1 0.38
Lupus medications at study visit, N (%)***
Topical/intralesional
corticosteroids
NA 5 (45) 7 (70) 0 (0) 0.005
Hydroxychloroquine NA 6 (54) 6 (60) 3 (33) 0.54
Chloroquine NA 3 (27) 1 (10) 0 (0) 0.35
Quinacrine NA 4 (36) 2 (20) 0 (0) 0.19
Methotrexate NA 2 (18) 0 (0) 1 (11) 0.62
Prednisone NA 0 (0) 4 (40) 6 (67) 0.003
Mycophenolate mofetil NA 1 (9) 5 (50) 1 (11) 0.09
Efalizumab NA 0 (0) 1 (10) 0 (0) 0.63
Leflunomide NA 0 (0) 1 (10) 0 (0) 0.63
None NA 2 (18) 0 (0) 2 (22) 0.42
SLE criteria, N (%)***
Malar rash NA 0 (0) 2 (20) 0 (0) 0.19
Discoid rash NA 11 (100) 10 (100) 0 (0) o0.00001
Photosensitivity NA 7 (64) 9 (90) 0 (0) 0.0001
Oral ulcers NA 2 (18) 6 (60) 0 (0) 0.008
Arthritis NA 2 (18) 6 (60) 6 (67) 0.07
Serositis NA 0 (0) 3 (30) 4 (44) 0.04
Renal disorder NA 0 (0) 4 (40) 6 (67) 0.01
Neurological disorder NA 0 (0) 0 (0) 1 (11) 0.30
Hematological disorder NA 1 (9) 8 (80) 9 (100) 0.00002
ANA NA 4 (36) 10 (100) 9 (100) 0.00008
Immunological disorder NA 0 (0) 7 (70) 9 (100) o0.00001
Abbreviations: ANA, antinuclear antibody; ANOVA, analysis of variance;
CLASI, Cutaneous Lupus Disease Activity and Severity Index; DLE, discoid
lupus erythematosus; NA, not applicable; SLE, systemic lupus erythema-
tosus; SLEDAI, Systemic Lupus Erythematosus Disease and Activity Index.
1SLEDAI values were not calculated for five DLESLE+ subjects.
*P-values were calculated using either one-way ANOVA tests (continuous
variables) or Fisher’s exact tests (categorical variables).
**P-values were calculated using Student’s t-tests between DLE+SLE and
DLE+SLE+ groups, because they were the only groups whose skin lesions
were evaluated with CLASI.
***P-value was calculated using one-way ANOVA tests among
DLE+SLE, DLE+SLE+, and DLE-SLE+ groups, because they were the
only groups whose disease activities were assessed using SLEDAI, and
whose lupus medications and SLE criteria were recorded.
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Table 2. Patient characteristics (cohort used for validation)
Normal DLE+SLE DLE+SLE+ DLESLE+1 P-value*
N 22 23 17 18 —
Gender (F) 19 20 16 16 0.93
Age at visit, mean (SD) 43 (11) 43 (11) 44 (12) 40 (13) 0.76
Ethnicity, N (%)
Caucasian 6 (27) 6 (26) 4 (23) 2 (11) 0.61
African American 14 (64) 16 (70) 10 (59) 11 (61) 0.90**
Hispanic 2 (9) 1 (4) 3 (18) 5 (28) 0.15
CLASI activity score, mean (SD)*** NA 7 (7) 10 (8)2 NA 0.27
CLASI damage score, mean (SD)*** NA 8 (5) 11 (8)2 NA 0.13
SLEDAI score, mean (SD)**** NA 1 (2) 4 (2) 2 (3)3 0.02
Lupus medications at study visit, N (%)****
Topical/intralesional corticosteroids NA 9 (39) 9 (53) 1 (6) 0.005
Hydroxychloroquine NA 14 (61) 11 (65) 6 (33) 0.12**
Chloroquine NA 3 (13) 1 (6) 0 (0) 0.30
Quinacrine NA 4 (17) 2 (12) 0 (0) 0.23
Methotrexate NA 2 (9) 0 (0) 1 (6) 0.77
Prednisone NA 0 (0) 7 (41) 12 (67) o0.00001
Mycophenolate mofetil NA 1 (4) 7 (41) 3 (17) 0.02
Efalizumab NA 0 (0) 1 (6) 0 (0) 0.30
Leflunomide NA 0 (0) 1 (6) 0 (0) 0.30
Cyclophosphamide NA 0 (0) 0 (0) 1 (6) 0.61
None NA 6 (26) 0 (0) 3 (17) 0.09
SLE criteria, N (%)***
Malar rash NA 1 (4) 4 (24) 1 (6) 0.14
Discoid rash NA 23 (100) 17 (100) 0 (0) o0.00001
Photosensitivity NA 15 (65) 15 (88) 2 (11) o0.00001
Oral ulcers NA 3 (13) 10 (59) 2 (11) 0.002
Arthritis NA 2 (9) 9 (53) 10 (56) 0.001
Serositis NA 0 (0) 4 (24) 7 (39) 0.001
Renal disorder NA 0 (0) 5 (29) 13 (72) o0.00001
Neurological disorder NA 0 (0) 0 (0) 1 (6) 0.60
Hematological disorder NA 3 (13) 13 (76) 15 (83) o0.00001
ANA NA 8 (35) 16 (94) 18 (100) o0.00001**
Immunological disorder NA 0 (0) 14 (82) 18 (100) o0.00001
Abbreviations: ANA, antinuclear antibody; ANOVA, analysis of variance; CLASI, Cutaneous Lupus Disease Activity and Severity Index; DLE, discoid lupus
erythematosus; NA, not applicable; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease and Activity Index.
11 DLE-SLE+ subject met three criteria (renal (kidney biopsy consistent with lupus nephritis), ANA, immunological disorder).
2CLASI activity and damage scores were not calculated for one DLE+SLE+ subject.
3SLEDAI values were not calculated for seven DLESLE+ subjects.
*P-values were calculated using either one-way ANOVA tests (continuous variables) or Fisher’s exact test (categorical variables).
**P-values were calculated using w2 tests.
***P-values were calculated using Student’s t-tests between DLE+SLE and DLE+SLE+ groups, because they were the only groups whose skin lesions were
evaluated with CLASI.
****P-value was calculated using one-way ANOVA tests among DLE+SLE, DLE+SLE+, and DLE-SLE+ groups, because they were the only groups whose
disease activities were assessed using SLEDAI, and whose lupus medications and SLE criteria were recorded.
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with all other groups, most notably DLEþ SLEþ subjects
(Po0.05) (Figure 1b–k).
Other IgG autoantibodies against non-nuclear antigens,
including c1q, fibrinogen I-S, and -rat glomeruli, were
at the highest levels in DLESLEþ subjects (Po0.05)
(Supplementary Figure S1a–c online). However, the NFIs of
these autoantibodies were significantly lower than those of
autoantibodies against nuclear antigens highlighted in
Figure 1. Antibodies against desmoglein-3, which is impor-
tant in keratinocyte adhesion, were distinctly elevated in
DLEþ SLE subjects versus DLESLEþ subjects (Supple-
mentary Figure S1d online).
We also examined for distinctly elevated autoantibodies in
DLEþ SLE subjects versus healthy controls. SAM analysis
yielded 10 autoantibodies (anti-a6b4 integrin, -b2-micro-
globulin, -fibrinogen IV, -heparan sulfate proteoglycan
(HSPG), -Jo-1, -Matrigel, -proliferating cell nuclear antigen,
-platelet-derived growth factor receptor sR alpha, -SS-A
(52 kDa), and -U1-snRNP-A) that were significantly upregu-
lated in DLEþ SLE subjects (qo0.05) (Supplementary
Figure S2a–j online). However, levels of all autoantibodies,
except for anti-HSPG, -Matrigel, and -a6b4 integrin anti-
bodies, in DLEþ SLE subjects were lower than those in
DLESLEþ subjects, which represented disease controls.
Orthogonal platforms confirm array trends in IgG
autoantibodies against nuclear antigens in DLE and SLE subjects
We performed ELISAs and fluorescent immunoassays using
an independent cohort of subjects to verify autoantigen
array trends in IgG autoantibodies against nuclear antigens.
Once again, anti-dsDNA, -ssDNA, and -SS-A (52 kDa)
IgG antibodies were significantly higher in DLESLEþ
subjects compared with the other three groups, including
DLEþ SLEþ subjects (Po0.005) (Figure 2a–c). DLESLEþ
and DLEþ SLEþ subjects expressed similarly elevated
amounts of anti-SS-A (60 kDa), -U1-snRNP-BB0, -histones,
and ANA IgG antibodies compared with DLEþ SLE and
healthy subjects (Po0.05) (Figure 2d–g). Anti-dsRNA, -
histone H1, -histone H2A, -histone H2B, and SS-B IgG
antibodies were not significantly different among the four
groups (data not shown). Comparison of autoantigen array
and immunoassay values for each subject showed strong
correlation for anti-dsDNA (Spearman’s r¼0.72, Po0.0001),
-SS-A (52 kDa) (Spearman’s r¼0.38, P¼0.01), -SS-A
(60 kDa) (Spearman’s r¼0.59, Po0.0001), and -ssDNA
(Spearman’s r¼0.78, Po0.0001) (Figure 2h–k).
In contrast, immunoassays measuring IgG autoantibodies
against selected skin antigens did not reflect similar trends
seen in the autoantigen arrays. We performed ELISAs
measuring IgG autoantibodies against the epidermal–dermal
junction proteins a6b4 integrin and HSPG, which were
upregulated on the arrays in DLEþ SLE subjects versus
healthy controls. DLEþ SLE and healthy subjects expressed
similar levels of IgG autoantibodies against a6b4 integrin and
HSPG. In addition, ELISAs evaluating anti-desmoglein-3 IgG
antibodies, which were downregulated in DLESLEþ
subjects in the arrays, showed no distinct differences (data
not shown).
Decreased IgM autoantibodies against selected antigens were
seen in SLE subjects
A heat map summarizing serum levels of IgM antibodies
against 85 autoantigens, which met NFI requirements, is
presented in Figure 3a. SAM analysis identified four auto-
antibodies (anti-alpha B crystallin, -desmoglein 3, -heat-shock
cognate 70, and -lipopolysaccharide) that were differentially
expressed in the four groups (asterisked in Figure 3a). IgM
autoantibodies against alpha B crystallin and lipopolysacchar-
ide were highest in healthy controls, followed by DLEþ SLE,
DLEþ SLEþ , and DLESLEþ subjects (Figure 3b and c).
IgM autoantibodies against heat-shock cognate 70 and
desmoglein-3 were elevated in healthy and DLEþ SLE
subjects than in the other groups (Figure 3d–e). SAM
analysis did not yield any significantly upregulated IgM
autoantibodies in DLEþ SLE subjects compared with healthy
controls.
Increased IgG:IgM ratios in autoantibodies against
predominantly nuclear antigens are seen in DLESLEþ
subjects
Ratios of IgG and IgM NFIs were calculated for each
differentially expressed IgG and IgM autoantibody among
the four groups. For all 15 differentially expressed IgG
autoantibodies, the highest IgG:IgM ratios were found in the
DLESLEþ group, with statistical significance being attained
with anti-dsDNA, -dsRNA, -fibrinogen I-S, -histone H2A and
H2B, -rat glomeruli, and –SS-A (60 kDa) antibodies (Po0.05)
(Figure 4a–g). Furthermore, in this group of autoantibodies, a
stepwise decrease in IgG:IgM ratio was noted from
DLESLEþ subjects to DLEþ SLEþ subjects and finally
both non-SLE groups. IgG:IgM ratios in the four differentially
expressed IgM autoantibodies failed to show significant
patterns in the four groups.
DISCUSSION
This study generated comprehensive autoantibody profiles of
DLE and SLE subjects using autoantigen arrays. Comparison
of these profiles showed that autoantibodies against various
nuclear antigens can stratify DLE and SLE subjects. Six
autoantibodies against dsDNA, dsRNA, histone H2A, histone
H2B, SS-A (52 kDa), and ssDNA showed distinctively
higher levels in DLESLEþ subjects compared with all other
groups, most notably DLEþ SLEþ subjects. Immunoassays
measuring IgG autoantibodies against dsDNA, ssDNA, and
SS-A (52 kDa) displayed this similar trend. Lower levels of IgG
autoantibodies against nuclear antigens in DLEþ SLEþ
subjects compared with DLESLEþ subjects imply that
DLE is a phenotypic marker associated with milder systemic
disease. A possible explanation for the decrease in IgG
autoantibodies against nuclear antigens in DLEþ SLEþ
versus DLESLEþ subjects is that the skin may serve as a
repository for autoantibody deposition in DLE patients and
decrease the number of circulating autoantibodies that could
inflict peripheral organ damage. Potential targets of auto-
antibodies in DLE skin include nuclear antigens from
keratinocytes. Cultured keratinocytes treated with UV light
have undergone apoptosis, exposed nuclear antigens, and
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shown increased binding to various autoantibodies such as
those targeting SS-A and SS-B (Furukawa et al., 1999).
Discoid lesions have been previously associated with
lower overall disease severity, specifically reduced renal
involvement and rates of positive ANAs (Gilliam et al., 1974;
Prystowsky and Gilliam, 1975; Callen, 1982). A comparison
of our DLESLEþ and DLEþ SLEþ subjects reveals that a
smaller portion of DLEþ SLEþ subjects had renal and
neurological disease, as well as serositis. A previous study
of 201 Puerto Ricans with SLE showed higher percentages of
positive tests for anti-Sm and RNP antibodies in DLESLEþ
subjects than in DLEþ SLEþ subjects, but actual autoanti-
body levels were not reported (Vila et al., 2006).
Our data showing elevated IgG autoantibodies against
nuclear antigens in SLE subjects are consistent with previous
observations in SLE patients (Adu et al., 1981). The
DLESLEþ group, which had the highest percentage of
renal disease, expressed the highest autoantibodies against
dsDNA and histone proteins, which are associated with lupus
nephritis (Adu et al., 1981; Cortes-Hernandez et al., 2004).
These autoantibodies correlate with disease activity in SLE
patients (Cortes-Hernandez et al., 2004). Anti-ssDNA, anti-
SS-A, and anti-RNP antibodies are found in at least half of all
SLE patients (Ignat et al., 2003; Li et al., 2010b). Apoptotic
activity in the kidney can lead to enhanced release of
nucleosomes containing DNA and histones, making them
prime targets for autoantibodies (Kalaaji et al., 2006).
Glomerular deposits of histones and nucleosomes have
been observed in human lupus nephritis kidneys, where
immune complexes accumulate and trigger lupus (van
Bruggen et al., 1997).
The predominant autoantibody in DLE patients remains
unknown. Various autoantibodies against nuclear antigens
including dsDNA, Smith, SS-A, SS-B, and ssDNA (Provost
et al., 1985; Wallace, 1993; Lee et al., 1994) have been
previously tested, but only low-titer anti-Ro (60 kDa) anti-
bodies have been found in most DLE patients (Lee et al.,
1994). Our autoantigen arrays provided a comprehensive
scan of autoantibodies in DLE sera by screening for 98
autoantibodies involved in various autoimmune systemic
and/or cutaneous diseases. Compared with healthy controls,
DLEþ SLE subjects had 10 upregulated autoantibodies,
which included three against nuclear antigens (Jo-1, U1-
snRNP-A0, SS-A (52 kDa)) and two against epidermal–dermal
junction proteins (HSPG, a6b4 integrin). The three antibodies
against nuclear antigens that were elevated in DLEþ SLE
subjects were markedly lower than in DLESLEþ subjects,
thus decreasing their specificity in DLE. ELISAs measuring
autoantibodies against HSPG and a6b4 integrin failed to
verify the autoantigen array results. This was likely due to
either relatively low NFIs (anti-a6b4 integrin antibody) or fold-
change differences (anti-HSPG antibody) in the autoantigen
arrays. On the basis of these findings and the results of
decreased autoantibodies against nuclear antigens in
DLEþ SLEþ versus DLESLEþ subjects, we hypothesize
that autoantibodies distinctly elevated in DLE patients may be
found in the skin rather than in the sera. Further studies
isolating antibodies deposited in DLE skin will be pursued.
Four distinct IgM autoantibodies identified as differentially
expressed among the four groups by SAM analysis tended to
have lower levels in the two SLE groups (DLEþ SLEþ and
DLESLEþ ) than the two non-SLE groups (DLEþ SLE and
healthy). Moreover, multiple other IgM autoantibodies,
which were in the same clusters as these aforementioned
antibodies, expressed a similar pattern among the groups.
These findings are consistent with our previous autoantigen
array findings that IgM autoantibodies were higher in
incomplete lupus erythematosus subjects (Li et al., 2007).
We hypothesize that because the vast majority of DLE
patients do not progress to SLE, specific IgM autoantibodies
may either halt or fail to induce systemic progression.
Lupus-prone MRL-lpr mice that could not secrete IgM
antibodies enhanced production of IgG autoantibodies
against dsDNA and histones compared with wild-type
MRL-lpr mice. Moreover, these mice had more severe
glomerulonephritis and shorter life span than their normal
counterparts (Boes et al., 2000).
We also observed a marked increase in IgG:IgM ratios in
autoantibodies that mainly targeted nuclear antigens (e.g.,
dsDNA, dsRNA, ssDNA) in DLESLEþ subjects compared
with the other subjects, especially DLEþ SLEþ subjects. This
trend mirrored that of the same IgG autoantibodies in the four
groups. This may relate to the ability of IgG autoantibodies to
elicit FcR-dependent pathogenic cascades in peripheral
organs. In addition, it may reflect a more robust class-
switching drive (with attendant somatic mutation) (Shlomchik
et al., 1990) among the DLESLEþ subjects, possibly
because of their genetic makeup, the nature of autoantigens
in these patients, or the antigenic or inflammatory milieu
within their germinal centers. Indeed, it would be interesting
to examine whether DLESLEþ subjects had more vibrant
germinal center responses. Finally, this may relate to the
potentially protective role of IgM autoantibodies, as pre-
viously demonstrated in IgM-deficient MRL-lpr mice (Boes
et al., 2000). This characteristic is likely limited to selected
IgM autoantibodies. Injection of anti-dsDNA IgM antibodies,
Figure 1. IgG autoantibody levels in discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) sera as determined by autoantigen arrays.
(a) We generated a heat map summarizing IgG reactivities in the four groups. Green, black, and red represent net fluorescence intensities (NFIs) below, close to,
and above the mean, respectively. Significance analysis of microarray (SAM) analysis identified differentially expressed autoantibodies (*qo0.05). The lower
right bracket spans autoantibodies targeting multiple nuclear antigens. (b–k) For each group, we plotted NFIs for differentially expressed IgG autoantibodies
against double-stranded DNA (dsDNA) (b), double-stranded RNA (dsRNA) (c), histone H2A (d), histone H2B (e), SS-A (52 kDa) (f), single-stranded DNA (ssDNA)
(g), histone H1 (h), SS-A (60 kDa) (i), U1-snRNP-BB0 (j), and centromere protein-A (CENP-A) (k). We performed secondary analyses using one-way analysis of
variance (ANOVA) with Tukey’s honestly significant difference (HSD) test for multiple comparisons. *Po0.05, **Po0.005, ***Po0.0005.
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but not anti-Sm and anti-phospholipid IgM antibodies, in
MRL-lpr mice alleviated lupus nephritis. This may be due to
decreased macrophage infiltration and cytokine production,
and more efficient clearance of apoptotic debris (Jiang et al.,
2011). The relative decrease in IgG:IgM autoantibodies
against these antigens in DLEþ SLEþ versus DLESLEþ
subjects may also explain the lower prevalence of lupus
nephritis in DLE patients (Prystowsky and Gilliam, 1975;
Merola et al., 2011). A prospective study following autoanti-
body profiles of these subjects and mechanistic studies in
MRL-lpr mice would further clarify the relative roles of IgG
and IgM autoantibodies in DLE and SLE.
Limitations of our study include small sample size,
selection bias, cross-sectional nature, and potential for falsely
significant autoantibodies. Despite our small sample size, we
still found significant differences in autoantibodies against
nuclear antigens between DLE and SLE subjects. Although
subjects were mostly selected from one tertiary referral
center, we were able to recruit DLE and SLE subjects with a
wide range of disease activity. A larger multicenter study
sampling the sera of DLE and SLE subjects is being planned to
verify our findings. In addition, sera from patients were
collected from only one visit. Comparing autoantibody
profiles at multiple visits from the same patients in a future
prospective study will help identify those whose levels
correlate with disease activity. Although sampling of multiple
autoantibodies can result in identifying autoantibodies that
are falsely significantly different, a false discovery rate of 5%
(q-value) on SAM analysis was established to minimize this
error, and immunoassays were performed to verify autoanti-
gen array results.
We have demonstrated that there are distinctive patterns
of IgG and IgM autoantibodies that may distinguish subsets of
DLE and SLE subjects. The vast majority of differentially
expressed IgG autoantibodies targeted nuclear antigens.
Specifically, DLESLEþ subjects expressed the highest level
of autoantibodies against dsDNA, dsRNA, histone H2A,
histone H2B, ssDNA, and SS-A (52 kDa) on autoantigen
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Figure 2. IgG autoantibodies against nuclear antigens in discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) sera using immunoassays.
(a–g) We performed ELISAs and fluorescent immunoassays to measure IgG autoantibodies against double-stranded DNA (dsDNA) (a), single-stranded DNA
(ssDNA) (b), SS-A (52 kDa) (c), SS-A (60 kDa) (d), U1-snRNP-BB0 (e), histones (f), and antinuclear antibody (ANA) (g). We performed one-way analysis of variance
(ANOVA) with Tukey’s honestly significant difference (HSD) test for multiple comparisons. (h–k) We generated correlation plots of immunoassay values (Uml1
or luminous unit (LU)) and autoantigen array net fluorescence intensities (NFIs) for each subject sample for anti-dsDNA (h), -SS-A (52 kDa) (i), -SS-A (60 kDa) (j),
and -ssDNA (k). Spearman’s r and corresponding P-values are reported for each graph. *Po0.05, **Po0.005, ***Po0.0005.
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Figure 4. IgG:IgM ratios of autoantibodies against selected antigens as determined by autoantigen arrays. (a-g) For each group, we plotted ratios of IgG and
IgM net fluorescence intensities (NFIs) for autoantibodies against double-stranded DNA (dsDNA) (a), double-stranded RNA (dsRNA) (b), fibrinogen I-S (c),
histone H2A (d), histone H2B (e), rat glomeruli (f), and SS-A (60 kDa) (g). We performed one-way analysis of variance (ANOVA) with Tukey’s honestly significant
difference (HSD) test for multiple comparisons. *Po0.05.
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Figure 3. IgM autoantibody levels in sera of discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) subjects as determined by autoantigen
arrays. (a) We generated a heat map summarizing IgM reactivities in the four groups. Green, black, and red represent net fluorescence intensities (NFIs) below,
close to, and above the mean, respectively. Significance analysis of microarray (SAM) analysis identified differentially expressed autoantibodies (*qo0.05). (b–e)
For each group, we plotted NFIs for IgM autoantibodies against alpha B crystallin (b), lipopolysaccharide (LPS) (c), heat-shock cognate 70 (Hsc70) (d), and
desmoglein-3 (e). We performed secondary analyses using one-way analysis of variance (ANOVA) with Tukey’s honestly significant difference (HSD) test for
multiple comparisons. *Po0.05, **Po0.005.
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arrays and immunoassays. The downregulation of these
autoantibodies in DLEþ SLEþ versus DLESLEþ subjects
supports previous clinical findings that DLE patients have
milder systemic disease. Downward trends in selected IgM
autoantibodies against alpha B crystallin, desmoglein 3, heat-
shock cognate 70, and lipopolysaccharide were noted in both
SLE groups. DLESLEþ subjects had the highest IgG:IgM
ratios against autoantibodies against mostly nuclear antigens.
We have hypothesized nonpathogenic roles for specific IgM
autoantibodies, which would require confirmation in larger
human sera studies. Future investigation into their function in
murine lupus models could provide new insights into
combating SLE.
MATERIALS AND METHODS
Subjects
This was a cross-sectional pilot study comparing serum autoantibody
values from age- and gender-matched DLE, SLE, and healthy
control subjects who presented to outpatient dermatology and
rheumatology clinics at the University of Texas Southwestern
Medical Center and Parkland Health and Hospital System in
Dallas, TX. All subjects were recruited from July 2003 to January
2011. All subjects consented by written agreement to inclusion in
this study, which was approved by the University of Texas
Southwestern Medical Center Institutional Review Board. The study
protocol and informed consent were in compliance with Declaration
of Helsinki Principles. A total of 18 DLESLEþ subjects, 17
DLEþ SLEþ subjects, 23 DLEþ SLE subjects, and 22 healthy
controls were recruited and enrolled into the Dallas Regional
Autoimmune Disease Registry and/or University of Texas South-
western Cutaneous Lupus Registry. The inclusion criteria for all
subjects were the ability to give written informed consent, and age
above 18 years. Subjects were excluded if they had drug-induced
SLE or DLE. Healthy controls were excluded if they had a history of
an autoimmune disease. DLESLEþ subjects were defined as those
meeting at least four ACR SLE diagnostic criteria (Tan et al., 1982)
without having a history of DLE. DLEþ SLEþ subjects fulfilled at
least four ACR SLE diagnostic criteria including DLE. The diagnosis
of DLE was based on clinicopathologic correlation. Although
carrying the DLE diagnosis, DLEþ SLE subjects had less than four
ACR SLE diagnostic criteria.
Data collection
At the time of enrollment, study subjects provided information on
demographics, past medical histories, and current treatments.
Cutaneous and systemic disease severities were assessed using the
Cutaneous Lupus Disease Activity and Severity Index (Albrecht et al.,
2005) and Systemic Lupus Erythematosus Disease Activity Index
(Bombardier et al., 1992), respectively. Other information such as
laboratory values and biopsy reports were obtained by medical chart
review.
Blood collection
Approximately 5ml of blood was drawn in serum separator tubes
from each subject. Sera were collected after centrifugation of blood
samples at 3,000 r.p.m. at room temperature for 10 minutes, and
stored in aliquots at 80 1C.
Autoantigen arrays
Autoantigen arrays were designed by plating recombinant or purified
proteins from 98 antigens, which were associated with either
autoimmune cutaneous diseases (Supplementary Table S1 online),
or systemic diseases, as previously described (Li et al., 2011). We
prepared antigens, coated slides, incubated patient serum, and
secondary fluorescently conjugated antibodies, as previously de-
scribed (Li et al., 2005, 2010a). A Genepix 4000B scanner
(Molecular Devices, Sunnyvale, CA) detected fluorescent signals
and generated images for analysis (Li et al., 2007). NFIs for IgG
autoantibodies were normalized by dividing background-adjusted
values by those from anti-human IgG in the array and multiplying the
ratio by 1,000. We excluded IgG and IgM autoantibodies whose
levels wereo1% of the highest NFI for all subject samples, as these
were regarded as noise.
Immunoassays
ELISAs were performed to measure IgG autoantibodies of interest
identified from the arrays with commercially available kits
(ANAs (INOVA Diagnostics, San Diego, CA), anti-dsDNA anti-
bodies, anti-ssDNA, anti-histones antibodies (ORGENTEC Diagnos-
tika, Mainz-Germany), and anti-desmoglein-3 antibodies (MBL
International, Woburn, MA)). Concentrations were extrapolated
from a standard curve. Established ELISA protocols (Shi et al.,
2002) were used to measure IgG autoantibodies against U1-snRNP-
BB0 (Surmodics, Eden Prairie, MN), histone H1 (Roche, Indianapolis,
IN), H2A, H2B proteins (New England BioLabs, Ipswich, MA),
dsRNA/polyinosinic-polycytidylic RNA (Sigma-Aldrich, St Louis,
MO), HSPG (Sigma-Aldrich), and a6b4 integrin (R&D Systems,
Minneapolis, MN) and IgM autoantibodies against lipopolysacchar-
ide (Sigma-Aldrich). OD450 was measured by an Elx800 microplate
reader (Biotek Instruments, Winooski, VT). Fluorescent immunoas-
says were performed to measure anti-SS-A (52 kDa), -SS-A (60kDa),
and SS-B IgG antibodies using QUANTA Plex (Luminex) kits (INOVA
Diagnostics).
Statistical analysis
Sample size was not calculated because of the pilot study design.
SAM analysis (http://www-stat.stanford.edu/~tibs/SAM/) was used to
determine autoantibodies with statistically significant differences
among groups. Heat maps were generated, and row-wise clustering
analysis was performed using the Cluster and Treeview software
(http://rana.lbl.gov/EisenSoftware.htm). Subject characteristics were
compared using one-way analysis of variance tests (continuous
variables), Student’s t-tests (continuous variables), or Fisher’s exact
tests (categorical variables). For the autoantibodies that were
identified to be differentially expressed by SAM analysis, secondary
analyses using one-way analysis of variance with Tukey’s honestly
significant difference tests were conducted to assess pairwise
differences among disease groups. The correlation between auto-
antigen array and immunoassay values for selected autoantibodies in
subject sera was assessed by calculating Spearman’s correlation
coefficient and accompanying P-values. Statistical significance was
declared for P-values (analysis of variance, Tukey’s test) and q-
values, which are defined as the lowest false discovery rate at which
the autoantibodies are called significant by SAM analysis (Tusher
et al., 2001), o0.05.
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